Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.
Effective treatment for Sjögren's syndrome (SS) might be developed locally by introducing genes encoding cytokines, which are potentially anti-inflammatory, or by introducing a cDNA encoding a soluble form of a key cytokine receptor, which can act as an antagonist and decrease the availability of certain cytokines, such as soluble tumour necrosis factor alpha receptors. Currently, the preferred choice of viral vector for immunomodulatory gene transfer is recombinant adeno-associated virus. The use of gene transfer to help determine the pathophysiology and to alter the course of the SS-like disease in the NOD mouse model can ultimately lead to the development of new treatments for managing the salivary component in patients with SS.
Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA. m.r.krok@amc.uva.nl
M R
MR
Kok
B J
BJ
Baum
P P
PP
Tak
S R
SR
Pillemer
D000818:Animals; D016207:Cytokines / Q000235:genetics*; D000229:Dependovirus / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics*; D012859:Sjogren's Syndrome / Q000276:immunology / Q000628:therapy*
D016207:Cytokines; D018124:Receptors, Tumor Necrosis Factor